Last Call for Med-e-Tel 2010 Early Bird Registration

14-16 April 2010, Luxembourg.
The Med-e-Tel forum is the ideal opportunity to follow up on the latest developments and initiatives in Telemedicine and eHealth and to exchange ideas and experiences related to ICT applications in healthcare. Register on or before Monday, 15th March, 2010 and get the early bird rate for your Med-e-Tel registration. This is a savings of 25% on the full registration fee, a full package offering you access to all Med-e-Tel conference sessions, expo and networking area, breaks, lunches, receptions, conference materials and wifi access at the conference venue.

Hear from the following speakers at the Med-e-Tel opening on Wednesday April 14th:

  • Mars Di Bartolomeo, Minister of Health, Luxembourg
  • Michael Nerlich, President, ISfTeH
  • Yunkap Kwankam, Executive Director, ISfTeH
  • Karl Brown, Associate Director, Rockefeller Foundation
  • Gérard Comyn, Former Head, ICT for Health, European Commission and Vice-President, CATEL
  • Peter Waegemann, Vice-President, mHealth Initiative
  • Joseph Dal Molin, President, e-cology and Director, WorldVistA
  • Tim Ellis, Programme Manager, Whole System Demonstrators, UK Dept. of Health
  • Günter Schreier, Head, Information Management & eHealth, Austrian Institute of Technology
  • Brenda Wiederhold, Secretary General, International Association for CyberTherapy, Training and Rehabilitation

And more keynote addresses at the Thursday April 15th plenary:

  • Valery Stolyar, Secretary, Russian Telemedicine Association
  • Feng Zhao, eHealth Coordinator/Senior Health Specialist, The World Bank
  • David Benton, CEO, International Council of Nurses
  • Mark Blatt, Global Director Health Industry Solutions, Digital Health Group, Intel

An extensive three day conference program with sessions on:

  • Benefits of Free/Libre Open Source Software in Health Care (FLOSS-HC)
  • Clinical Telemedicine Course
  • Closing the Healthcare Gap in Developing Countries
  • Cost Effectiveness
  • E-Mental Health: Enhancing Mental Health Services Through Information and Communication Technology
  • eLearning
  • Electronic Health Records
  • Ethics and Acceptance
  • Framework for Development of International Quality Standards for Teleconsultation Centers (Advisory Committee Meeting)
  • HHR for eHealth: What Needs, What Options, What Solutions?
  • Home Care and Assisted Living
  • Improving Electronic Care Record Keeping, Boosting Productivity, Accountability and Quality of Social Care
  • International Telemedicine and eHealth Initiatives and Developments
  • Medical Informatics
  • Mobile Health
  • New Models of Care and the Use of New ICT Solutions
  • Standardization and eHealth
  • Telecardiology
  • Teleconsultations and Remote Treatment
  • Telemonitoring
  • Telenursing
  • Telesurgery and Wound Care
  • Virtual Reality and Rehabilitation

For further information and registration, please visit:
http://www.medetel.eu

About Med-e-Tel
Med-e-Tel focuses on ehealth and telemedicine applications and a wide range of other medical ICT applications and on the convergence of information and communication technology with medical applications, which lead to higher quality of care, cost reductions, workflow efficiency, and widespread availability of healthcare services.

The "Med" in Med-e-Tel stands for healthcare services (institutional and home based care, prevention and education) and for medical products and equipment (medical imaging equipment, monitoring devices, electronic health records, etc.).
The "e" stands for the electronic and IT industry and services (hard- & software, internet, e-mail, etc.).
The "Tel" stands for telecommunications (whether it is POTS, ISDN, wireless, satellite, videoconferencing, VoIP, or other).

For further information, please visit www.medetel.eu.

Most Popular Now

Xenpozyme™ (olipudase alfa-rpcp) approved by FDA a…

The U.S. Food and Drug Administration (FDA) has approved Xenpozyme™ (olipudase alfa-rpcp) for the treatment of non-central nervous system (non-CNS) manifestations of acid...

FDA grants Breakthrough Therapy Designation to Pfi…

Pfizer Inc. (NYSE:PFE) today announced that its investigational Group B Streptococcus (GBS) vaccine candidate, GBS6 or PF-06760805, received Breakthrough Therapy Designat...

Malaria booster vaccine shows durable high efficac…

Researchers from the University of Oxford and their partners have today reported new findings from their Phase 2b trial following the administration of a booster dose of ...

Research reveals widespread use of ineffective COV…

Monoclonal antibodies are laboratory-designed treatments tailor-made to fight specific infections. In early 2021, the U.S. Food & Drug Administration issued emergency use...

Strict COVID lockdowns in France improved cardiova…

A new paper in European Heart Journal - Digital Health, published by Oxford University Press, indicates that social-distancing measures like total lockdown have a measura...

Efficacy, cash and more will increase booster shot…

The more effective the COVID-19 booster, the more likely people are to get it, according to new Cornell research. And they are more likely to accept the booster shot with...

U.S. clinical trial evaluating antiviral for monke…

A Phase 3 clinical trial evaluating the antiviral tecovirimat, also known as TPOXX, is now enrolling adults and children with monkeypox infection in the United States. St...

Stem cell-gene therapy shows promise in ALS safety…

Cedars-Sinai investigators have developed an investigational therapy using support cells and a protective protein that can be delivered past the blood-brain barrier. This...

Novartis invests in early technical development ca…

Novartis today announced it is investing in next-generation biotherapeutics with the creation of a fully integrated, dedicated USD 300m scientific environment that will b...

Drug turns cancer gene into "eat me" fla…

Tumor cells are notoriously good at evading the human immune system; they put up physical walls, wear disguises and handcuff the immune system with molecular tricks. Now...

Mucosal antibodies in the airways protect against …

High levels of mucosal antibodies in the airways reduce the risk of being infected by omicron, but many do not receive detectable antibodies in the airways despite three ...

Pfizer and BioNTech receive positive CHMP opinion …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a 30-µg booster dose of their Omicron BA.4/BA.5 bivalent-adapted COVID-19 vaccine (COMIRNATY® Original/Om...